al alone or a lack of both subjective arousal and awareness of genital congestion (Table 1) . No objective measurements are used to establish diagnoses. Arousal disorders also have an uncertain prevalence; most studies focus only on vaginal lubrication. In a survey of 979 British women who were 18 to 70 years of age, 17 percent identified problems with arousal (defined as distinct from vaginal dryness) 14 ; 5 percent of women in SWAN did as well. 11
Factors Influencing Desire and Arousal
The basis of desire and perceived arousal in women is poorly understood, but it appears to involve 
APA Definition* AUA Foundation Definition † Comments
Hypoactive sexual desire disorder Disorder is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity. Judgment of deficiency is made by the clinician, taking into account factors that affect sexual functioning (such as age and context of the person's life).
Sexual desire/interest disorder Disorder is characterized by absent or diminished feelings of sexual interest or desire, absent sexual thoughts or fantasies, and a lack of responsive desire. Motivations for attempting to become sexually aroused are scarce or absent. Lack of interest goes beyond a normal lessening with increasing age and relationship duration.
Minimal spontaneous sexual thinking or minimal desiring of sex ahead of sexual experiences does not necessarily constitute a disorder (according to data on women in sexually satisfactory, established relationships). Lack of desire triggered during the sexual encounter (i.e., responsive desire) is integral to the AUA Foundation diagnosis.
Lack of subjective arousal
No DSM-IV definition addresses the lack of subjective arousal.
Combined arousal disorder Disorder is characterized by absent or markedly reduced feelings of sexual arousal (sexual excitement and sexual pleasure) from any type of stimulation, and absent or impaired genital sexual arousal (vulval swelling and lubrication).
There is no sexual excitement in the mind and no awareness of reflexive genital vasocongestion.
Subjective arousal disorder Disorder is characterized by absent or markedly reduced feelings of sexual arousal (sexual excitement and sexual pleasure) from any type of stimulation. Vaginal lubrication and other signs of physical response still occur.
There is no sexual excitement in the mind, but there is awareness of adequate lubrication.
Female sexual arousal disorder Disorder is characterized by a persistent or recurrent inability to attain, or to maintain until completion of sexual activity, adequate lubrication and swelling response of sexual excitement.
Genital arousal disorder Disorder is characterized by absent or impaired genital sexual arousal (minimal vulval swelling or vaginal lubrication from any type of sexual stimulation, and reduced sexual sensations when genitalia are caressed). Subjective sexual excitement still occurs from nongenital sexual stimuli.
The presence of subjective arousal (sexual excitement) from nongenital stimuli (e.g., erotica, stimulating the partner, receiving breast stimulation, kissing) is key to the AUA Foundation diagnosis.
Female orgasmic disorder Disorder is characterized by a persistent or recurrent delay or absence of orgasm after a normal sexual excitement phase.
Orgasmic disorder
Disorder is characterized by a lack of orgasm, markedly diminished intensity of orgasmic sensations, or marked delay of orgasm from any kind of stimulation, despite selfreported high sexual arousal or excitement.
Women with arousal disorders rarely or never experience orgasm and are frequently given a misdiagnosis of orgasmic disorder.
interactions among multiple neurotransmitters, sex hormones, and environmental factors.
Physiologic Factors
Genital vasocongestive responses occur in women within seconds after erotic stimulation. 15 Both parasympathetic and sympathetic nerves release nitric oxide and vasointestinal polypeptide, which mediate vasodilatation, and acetylcholine, which blocks noradrenergic, vasoconstrictive mechanisms and promotes endothelial release of nitric oxide. Pelvic sympathetic nerves also release norepinephrine, which is predominantly vasoconstrictive. The mediators of vaginal vasocongestion are less clear but include vasoactive intestinal polypeptide. The relaxation of vaginal smooth muscle permits vaginal expansion, and arteriolar dilatation increases the transudation of interstitial fluid, which promotes lubrication.
The effect of estrogen levels on sexual function is complex. Although low estrogen levels and vaginal atrophy are associated with reduced measures of vaginal congestion when the woman is not receiving sexual stimulation, the percent increase in congestion in response to erotic stimuli is similar in the presence of low and high estrogen levels. 15 Similarly, changes in the volume of the vaginal wall and clitoris and the relative volume of regional blood in response to sexual stimulation are similar before and after menopause. 16 Estrogen deficiency does not necessarily preclude adequate lubrication, provided that stimulation is sufficient. 15 However, up to 40 percent of women may have symptomatic vaginal atrophy that adversely affects sexual function. 17 Subjective arousal is poorly correlated with genital response. For example, increases in genital vasocongestion in response to erotic videos are similar among women who report problems with arousal and women who report no problems with arousal. 15 Also, there is a low correlation between brain activation in areas controlling genital response (as assessed by functional magnetic resonance imaging of the brain) and simultaneous ratings of subjective arousal. 18 Indirect evidence suggests that testosterone and dopamine play a role in modulating sexual response, since testosterone supplementation or treatment with a dopaminergic agonist can augment response. [5] [6] [7] [8] 19 Underproduction of androgen in women -as may occur with adrenal disease, after bilateral oophorectomy, or during normal aging -is sometimes associated with reduced desire and arousal. However, large population studies have failed to find the expected positive correlations between sexual function and serum testosterone levels. 20,21 One possible explanation is that serum levels do not reflect the intracellular production of testosterone from adrenal and ovarian precursors. 22 
Other Factors
Several factors have been associated with reduced subjective arousal. These include distractions, expectations of a negative experience (e.g., as a result of dyspareunia, the partner's sexual dysfunction, or negative experiences in the past), sexual anxiety, fatigue, and depression. Medications including selective serotonin-reuptake inhibitors 23 and oral contraceptives 24 have also been implicated. Oral contraceptives increase levels of sex hormone-binding globulin, which in turn reduces free testosterone levels; it is hypothesized that some women are particularly sensitive to these effects, which may be prolonged. 25 In a 1-year prospective study, 19 of 79 women who received oral contraceptives reported a decline in sexual desire; 37 discontinued oral contraceptive use within 12 months, many because of sexual side effects. 24 On the basis of survey data, several factors have been closely linked to women's sexual satisfaction and desire. These include stable past and current mental health, 3,4,13 positive emotional well-being and self-image, 13 rewarding past sexual experiences, 26 positive feelings for the partner, 13,26 and positive expectations for the relationship. 3,11 The partner's sexual dysfunction, 13 increased perceived stress, 3 a history of infertility especially after extensive investigation, 27 and increased duration of the relationship 11,26 are all linked with reduced desire. Certain diseases such as multiple sclerosis, 28 renal failure, 29 and premature menopause induced by chemotherapy 30 are associated with a high incidence of sexual dysfunction. In women, unlike men, vascular disease related to age does not appear to correlate with reduced sexual satisfaction. 3
S tr ategies a nd Ev idence

Evaluation
A detailed history is the main tool in the assessment and diagnosis of sexual dysfunction and is usually obtained from both partners (Table 2) . Im-portant aspects of the history include the quality of the couple's relationship, the woman's mental and emotional health, the quality of past sexual experiences, specific concerns related to sexual activity (such as insufficient nongenital and nonpenetrative genital stimulation), and the woman's thoughts and emotions during sexual activity.
A physical examination, including a pelvic examination (Table 3) , is part of routine care, but it infrequently identifies a cause of sexual dysfunction. Its usefulness may be greater when there is associated dyspareunia. For some women with a history of coercive or abusive sexual experiences, pelvic examination may cause anxiety; explanation of what will and will not be done may reduce such anxiety.
The possibility that laboratory testing will identify causes of sexual dysfunction is low. Estro- 
Information Requested Details from the Couple
Sexual problem and reason for seeking help at this time Ask patients to describe problems in their own words, request clarification with direct questions, provide options rather than ask leading questions, provide support and encouragement, acknowledge their embarrassment, and reassure patients that sexual problems are common.
Duration, consistency, and priority of problems Clarify whether problems are present in all situations. If there is more than one problem, which is most troubling?
Context of sexual problems Assess the emotional intimacy of the couple, activity or behavior just before sexual activity, degree of privacy they have during sexual activity, degree of sexual communication, time of day and fatigue level when sexual activity occurs, use of birth control (adequacy, type), risk of sexually transmitted diseases, usefulness of sexual stimulation, and sexual knowledge.
Each partner's sexual response other than that related to the problem Elicit this information with respect to the present and the period before the onset of the problem.
Reaction of each partner to the problem Determine how each has reacted emotionally, sexually, and behaviorally.
Previous help sought by either partner Assess compliance with the previous recommendations and their effectiveness.
Details from Each Partner When Seen Alone
Partner's own assessment of the problem Symptom severity (e.g., total lack of desire) may be easier to disclose in the partner's absence.
Sexual response with self-stimulation Also inquire about sexual thoughts and fantasies.
Past sexual experiences Discuss positive and negative aspects.
Developmental history Determine relationships to others in the home during childhood and adolescence. Were there losses or traumas? Was he or she emotionally close to anyone? Was he or she given physical affection, love, and respect?
Past or current sexual, emotional, or physical abuse Explain that questions about abuse are routine and do not necessarily imply causation of sexual problems. It is helpful to ask whether the partner has ever felt hurt or threatened in the current relationship and, if so, whether he or she wishes to give more information.
Physical health, especially conditions leading to debility and fatigue, impaired mobility, or difficulties with selfimage (e.g., from the presence of stomas, disfiguring surgery, or incontinence)
Ask specifically about medications with known sexual side effects, including selective serotonin-reuptake inhibitors, beta-blockers, antiandrogens, gonadotropinreleasing hormone agonists, and oral contraceptives.
Evaluation of mood Correlation of sexual function and mood (including anxiety and depression) warrants routine screening for a mood disorder, by means of either a questionnaire (e.g., the Beck Depression Inventory) or a semistructured series of questions.
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gen deficiency, for example, is best detected by taking a history and performing an examination. Even when signs of estrogen deficiency are present, it is not necessarily the cause of sexual dysfunction. In addition, as noted, serum levels of testosterone do not correlate with sexual function. 20,21 Measurement of prolactin or thyrotropin is warranted if other symptoms or signs suggest the presence of abnormal levels.
Management
The management of sexual dysfunction in women is guided by the history. Data from randomized trials that support the use of any particular intervention are limited.
Psychological Interventions
Cognitive behavioral therapy focuses on identifying and modifying factors that contribute to sexual dysfunction, such as maladaptive thoughts, unreasonable expectations, behaviors that reduce the partner's interest or trust (such as disrespectful behavior or lack of honesty), insufficient erotic stimuli, and insufficient nongenital physical stimulation. Strategies are suggested to improve the couple's emotional closeness and communication and to enhance erotic stimulation. The sessions vary in number and usually include both partners. Sex therapy for couples is focused on similar issues but also includes sensate focus techniques, consisting initially of nonsexual physical touch, with gradual progression toward sexual touch; partners are encouraged to alternately touch each other and to provide feedback about what touches are pleasurable. These techniques help change the undue focus on a performance goal (e.g., one partner's orgasm or mutual orgasms). 31 Controlled studies that provide support for the use of this approach are scant, but in one that combined both cognitive behavioral therapy and sex therapy, 74 percent of women had improved sexual and marital satisfaction. 31 Satisfaction was maintained in 64 percent of women at one year, as compared with minimal improvement in a control group. Another intervention is short-term psychotherapy, generally focused on poor sexual self-image and on nonsexual experiences in childhood that are considered to relate to current sexual function (e.g., a chaotic upbringing that predisposed a woman to need to be in control could interfere with her "letting go" sexually as an adult). Data regarding the benefits of this approach are lacking. 32
Pharmacologic Interventions
Other than estrogen therapy for dyspareunia related to genitourinary atrophy, no medications are currently approved by the Food and Drug Administration for the treatment of sexual dysfunction in women. Several off-label uses of drugs have been considered, although data about effectiveness are sparse (Table 4) .
Nonhormonal Therapies
The involvement of nitric oxide in neurogenic vasodilatation suggests that phosphodiesterase inhibitors may ameliorate genital arousal disorder. In a small, laboratory-based, randomized trial, a single 50-mg dose of sildenafil (Viagra, Pfizer) increased subjective arousal, genital sensations, and ease of orgasm in some women with genital arousal disorder. 41 The benefit was observed only among women who had a marked reduction in the normal vasocongestive response to subjectively arousing visual erotic stimulation. In two large, randomized clinical trials involving 781 women in whom arousal and desire disorders (rather than genital arousal disorder) were diagnosed, sildenafil improved no measure of sexual desire, sensation, lubrication, or satisfaction. 38
Hormonal Therapies
Androgen Therapies
Supraphysiologic androgen therapy has been prescribed for sexual dysfunction since the 1930s, but more recently, testosterone at lower doses than originally prescribed have been studied in randomized trials. In one recent randomized, controlled trial involving 218 women who had undergone a natural or surgically induced menopause and who received 0.625 μg of esterified estrogens daily, the addition of 1.25 mg of methyltestosterone improved sexual responsiveness and the level of desire, as reported on one of two validated questionnaires used. 43 However, the frequency of desire was not affected, and measures of desire and composite sexual function were not significantly improved, according to responses on the second questionnaire. Also, the women who had undergone natural menopause were not prescribed progestin, which limited the clinical relevance of these results. Methyltestosterone is known to lower high-density lipoprotein (HDL) cholesterol, and in this study, levels fell by a mean of 12.5 mg per deciliter (0.3 mmol per liter) after four months of treatment.
The results of four recent placebo-controlled, randomized trials involving a total of 1619 women who had undergone surgically induced menopause show the efficacy of a 300-μg testosterone patch applied twice weekly. 5-8 All participants were treated with estrogen (delivered transdermally in one study, 8 orally in another, 6 and by either route in two studies 5,7 ), and the number of sexually satisfying events at baseline ranged from one to three per month. Pooling the data revealed that women receiving testosterone reported 1.9 more sexually satisfying events per month than they had at baseline, as compared with 0.9 more among those receiving placebo. Scores from validated questionnaires in each of the four studies showed a significant increase in sexual desire and response, and scores in three of the studies showed significant reductions in sexual distress. 5, 7, 8 One study also evaluated a twice-weekly patch containing 450 μg of testosterone; in contrast to the results for the lower-dose patch, no benefits were found. 6 Unwanted androgenic effects, including hirsutism and acne, were uncommon in all studies, but depilation rates were not assessed. Unlike with methyltestosterone, there were no significant changes in lipid levels. Important limitations of these four studies include their brevity (which is of particular importance, given the expected long-term use of the drug) and that their results are generalizable only to women in whom menopause was surgically induced and who also receive estrogen therapy. In some women who have undergone natural menopause, the ovaries continue to be an important source of androgens, 44 and thus, the effects of androgen supplementation may differ from those in women whose ovaries have been surgically removed. Furthermore, risks associated with the long-term use of conjugated estrogens arouse concern about the use of any postmenopausal estrogen therapy over time. Prescribing testosterone alone to women who lack estrogen would raise their already high ratios of androgen to estrogen. There are no safety or efficacy data for testosterone supplementation for estrogen-deficient women.
A chief concern with long-term androgen use is a potential increase in insulin resistance, which could predispose a woman to the metabolic syndrome or exacerbate the syndrome if it is already present. In SWAN, low levels of sex hormone-binding globulin and higher circulating levels of androgen were strongly associated with markers of the metabolic syndrome, including a high bodymass index; a high waist-to-hip ratio; presence of glucose intolerance, hypertriglyceridemia, or hypertension; and a low level of HDL cholesterol. 20
Dehydroepiandrosterone
Because middle-aged and older women have a physiologic decrease of as much as 70 percent in the amount of dehydroepiandrosterone produced, 22 In one small, four-month study, 19 nondepressed, premenopausal women showed increased arousability and sexual response but not initial desire.
Testosterone (plus estrogen) In six-month randomized trials, 5-8 women had improved "total satisfying sexual activity" and improved measures of desire and response, as reported on questionnaires. No long-term safety data or data on women lacking estrogen are available.
Dehydroepiandrosterone (a precursor of estradiol and testosterone)
Data from trials involving women with adrenal insufficiency are conflicting. 33-35 A study of perimenopausal women with reduced feelings of well-being and low level of desire showed no benefit.
36
Tibolone (an estrogenic, progestogenic, androgenic steroid)
Data from small trials of postmenopausal women show improved sexual function, as compared with those receiving placebo or a regimen of 17β-estradiol (1 mg daily) plus norethindrone (1 mg daily). 37 The drug has not been studied in women with diagnosed sexual dysfunction and is associated with a possible increased risk of breast cancer.
Phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil) †
In large multicenter trials involving pre-and postmenopausal women, 38 no benefit from sildenafil was reported.
Yohimbine (a centrally acting noradrenergic agent) plus arginine (a precursor of nitric oxide)
In one randomized, controlled crossover laboratory study of 24 women, yohimbine (6 mg) plus arginine (6 g) increased vaginal congestion, but not subjective arousal, in response to an erotic film. 39
Ephedrine (agonist of α-and β-adrenergic receptors)
In one randomized, controlled crossover laboratory study of 20 women, ephedrine (50 mg) increased vaginal congestion, but not subjective arousal, in response to an erotic film.
40
Genital arousal disorder despite estrogen-replete status
In one laboratory randomized trial, 41 it was shown that only some women given a diagnosis of genital arousal disorder have demonstrably reduced genital congestion, and they alone showed evidence of benefit. It was not possible clinically to distinguish this subgroup. In one randomized study of neurogenic genital arousal disorder from multiple sclerosis, some researchers have suggested that supplementation with the steroid may improve sexual function. However, rigorous data that support such supplementation are lacking. Even among women with adrenal insufficiency, the results of randomized trials of dehydroepiandrosterone supplementation have been inconsistent. [33] [34] [35] 
Estrogen
The role of systemic estrogen in increasing desire and subjective arousal remains unclear. In patients with vasomotor symptoms and insomnia or reduced levels of desire because of dyspareunia due to genital atrophy, it is logical to conclude that estrogen supplementation would increase sexual motivation, although this has not been rigorously tested. In the Women's Health Initiative trial, no significant differences were found between the estrogen and placebo groups in reported satisfaction after sexual activity. 45 However, sexual dysfunction was not a primary focus of the trial, and the assessment tool was inadequate.
Sexual Dysfunction Associated with Antidepressants
The prevalence of sexual disorders that are associated with the use of antidepressants in women is estimated at 22 to 58 percent, with higher rates reported for selective serotonin-reuptake inhibitors and lower rates reported for bupropion than for other drugs. 46 A recent Cochrane review of strategies to ameliorate dysfunction associated with antidepressants did not recommend any particular drug, although the potential advantages of adding bupropion were noted. 46 A drug holiday (e.g., halting the use of shorter-acting selective serotonin-reuptake inhibitors over the weekend) seems to be a logical strategy but is not recommended, owing to withdrawal symptoms and compromise of compliance.
A r e a s of Uncerta int y A better understanding is needed of the endogenous and environmental factors that mediate sexual desire and arousal. Randomized clinical trials are also needed to assess the effects of psychological and pharmacologic therapies alone and in combination. The risks and benefits of long-term testosterone therapy require further study, including studies of women with a complete loss of arousal and desire.
Guidelines
Recommendations for the evaluation and management of sexual dysfunction in women have been put forth by the American College of Obstetricians and Gynecologists, 47 the Society of Obstetricians and Gynaecologists of Canada, 48 the North American Menopause Society, 49 and the members of the 2003 International Consensus on Sexual Medicine (organized by the International Consultation on Urological Disease, the International Society for Urology, and the International Society for Sexual Medicine). 50 These organizations advocate attention to mental and overall health and to both interpersonal and personal psychological issues. Local estrogen therapy is recommended for dyspareunia that is associated with vulval atrophy that results in reduced sexual motivation.
The Society of Obstetricians and Gynaecologists of Canada notes that testosterone therapy should be viewed as investigational and should be prescribed only by clinicians who are knowledgeable about sexual dysfunction in women. 48 The recent position statement of the North American Menopause Society provides cautious support for the use of testosterone "in appropriate post-menopausal women via transdermal patches or topical gels or creams administered at the lowest dose for the shortest time that meets treatment goals." 49 Counseling about the potential risks and benefits of testosterone use is also advocated, as is evaluation for causes of low levels of desire (including physical and psychosocial factors and medications) before treatment.
Conclusions a nd R ecommendations
For women with desire and arousal disorders, such as the woman described in the vignette, the evaluation involves taking a detailed history of sexual difficulties from both partners, preferably seen individually as well as together. Also included are an assessment of the woman's mental health (including self-image), feelings about the relationship, medical history, and her thoughts and emotions during sexual activity. On the basis of clinical experience and limited data on outcomes, I would recommend a combination of cognitive behavioral therapy and sex therapy (typically three to six sessions). Sessions should be focused on altering maladaptive thoughts, unreasonable expectations, and misinformation about women's sexuality, as well as on discussing strategies for improving the couple's emotional closeness and communication and enhancing erotic stimulation. If the couple is excessively focused on intercourse (as is common if there is a history of infertility), they should be advised to emphasize nongenital stimulation first. Any apparent interpersonal problems should be addressed before further sexual therapy is pursued. At the present time, I would not recommend any pharmacologic therapy, pending the availability of more (and longer-term) data in support of such treatment.
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